GlassScriptPhysician profile
Kelly Goodwin
NPI 1528788403
$2,067.27
in general payments reported to CMS, 2019-2025
14 companies · $707 in 2025
The $707 reported for 2025 was more than what 81% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $277 · 2023: $697 · 2024: $386 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,790.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $402.83 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $200.00 | 2023-2024 | Lifevest |
| Teva Pharmaceuticals USA, INC. | $166.83 | 2022-2023 | Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $139.67 | 2025 | |
| Dexcom, INC. | $139.64 | 2023-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Dermavant Sciences, INC. | $124.99 | 2023 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.99 | 2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $121.87 | 2023 | Gvoke Hypopen |
| Genzyme Corporation | $120.41 | 2025 | |
| Gilead Sciences, INC. | $119.30 | 2025 | Descovy |
| Alexion Pharmaceuticals, INC. | $108.66 | 2022 | |
| Insmed, INC. | $102.35 | 2025 | Arikayce |
| Viiv Healthcare Company | $102.30 | 2025 | Apretude |
| Neurelis, INC. | $93.43 | 2023 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Goodwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.